Chen, Shengquan – Trademark Portfolio
Entity Type: 01
Chen, Shengquan owns a portfolio of 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as BELOAK, BIOIVE, CIBKWV, DEVARK, and LASXYF. Of these, 17 are registered. The portfolio spans 7 Nice Classification classes, led by Class 25 (Clothing) and Class 28 (Toys & Sporting Goods). Headquartered in Hunan.
Jianghua Yao Autonomous County
No. 69, Longshan Village, Tao xu Town
Hunan 425505 , CN
Showing of trademarks Trademarks
Trademark Classifications
Chen, Shengquan's trademark portfolio spans 7 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Games and playthings; gymnastic and sporting articles; decorations for Christmas trees
Apparatus for lighting, heating, steam generating, cooking, refrigerating, drying
Lace and embroidery, ribbons and braid; buttons, hooks and eyes, pins and needles
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Chen, Shengquan have?
Chen, Shengquan has 18 U.S. trademarks filed with the USPTO. Of these, 17 registered, 1 cancelled.
What trademark classes does Chen, Shengquan file in?
Chen, Shengquan files trademarks across 7 Nice Classification classes. The most active classes are Class 25 (Clothing), Class 28 (Toys & Sporting Goods), Class 11 (Environmental Control), Class 12 (Vehicles), Class 21 (Housewares). Class 25 covers clothing, footwear, headgear.
What are Chen, Shengquan's most well-known trademarks?
Chen, Shengquan's registered trademark portfolio includes well-known marks such as BELOAK, BIOIVE, CIBKWV, DEVARK, and LASXYF. These are among 17 currently registered trademarks in the portfolio.
What is Chen, Shengquan's trademark registration success rate?
Chen, Shengquan has a 94% trademark registration rate, with 17 out of 18 resolved applications resulting in successful registration. Currently, 0 applications are pending review.